Fusix Biotech develops the InFUSE platform, a proprietary oncolytic virus technology that utilizes fusogenic cell death to enhance immune response and effectively eliminate tumor cells. The platform addresses the need for safe and efficient cancer therapies by providing a novel treatment option with a strong safety profile and easy intravenous delivery.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often lack the ability to effectively target and eliminate tumor cells while also stimulating a robust and sustained anti-tumor immune response, leading to limited efficacy and potential for recurrence. Many solid tumors are also refractory to standard immunotherapy approaches due to the suppressive tumor microenvironment.
Solution
Fusix Biotech develops the InFUSE platform, a novel oncolytic virus technology designed to enhance immune response and efficiently eliminate tumor cells through fusogenic cell death. The InFUSE platform utilizes a unique hybrid virus construct combining features of two clinically validated oncolytic viral vectors to maximize therapeutic effects and maintain a strong safety profile. Upon infecting cancer cells, FUSE vectors replicate, leading to cell fusion and lysis, triggering an inflammatory reaction that alerts the immune system to the tumor's presence. This process primes key immune cells to target and eliminate the cancer, converting immune-suppressed tumors into immune-stimulatory ones, potentially sensitizing them to other immunotherapies.
Target Audience
Fusix Biotech's primary target audience includes pharmaceutical and biotechnology companies, clinical researchers, and investors focused on developing innovative cancer immunotherapies.
Features
- Hybrid virus construct combining advantageous features of two clinically validated oncolytic viral vectors
- Fusogenic cell death mechanism for enhanced tumor cell lysis
- Local release of therapeutic payload within the tumor microenvironment
- Activation of immune cells and priming of a systemic anti-tumor immune response
- Induction of local inflammation in the tumor to enable synergistic effects with other immunotherapeutic approaches
- GMP-compliant, scalable production processes for consistent and reliable manufacturing
- Modular vector design allowing for customization with various therapeutic payloads
- Preclinical efficacy demonstrated in multiple predictive solid tumor models, including liver, pancreatic, lung, and breast cancers